Advenchen 
Welcome,         Profile    Billing    Logout  
 5 Products   33 Diseases   5 Products   1369 Trials   5508 News 


«12...1213141516171819202122...4748»
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm, Zejula (niraparib) / GSK, J&J, Takeda
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy:  CC-ANNIE: Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma. (clinicaltrials.gov) -  Jan 31, 2023   
    P2,  N=6, Completed, 
    The study will also be supervised and managed by the Ethics Committee. Not yet recruiting --> Completed | N=20 --> 6 | Trial completion date: Jul 2023 --> Jan 2023 | Trial primary completion date: Jun 2023 --> Jan 2023
  • ||||||||||  Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial completion date, Trial primary completion date, Tumor mutational burden, IO biomarker, Metastases:  Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations (clinicaltrials.gov) -  Jan 26, 2023   
    P2,  N=21, Active, not recruiting, 
    The combination of anlotinib and irinotecan has promising anti-tumor activity in the second-line treatment of mCRC with a manageable safety profile. Trial completion date: Jun 2022 --> Mar 2023 | Trial primary completion date: Jun 2022 --> Mar 2023
  • ||||||||||  Tagrisso (osimertinib) / AstraZeneca, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Journal:  Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis. (Pubmed Central) -  Jan 22, 2023   
    Mechanistically, we confirmed that MYC binds to the promoter of AXL to promote its transcription in NSCLC cells, and we demonstrated that anlotinib combined with osimertinib treatment enhances the anti-tumor effect by inactivating the c-MET/MYC/AXL axis to reverse osimertinib resistance in NSCLC. In conclusion, our results provide strong support that this combination therapy may be effective in enhancing the efficacy of treatments in patients with advanced NSCLC.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Surgery, Metastases, Post-surgery:  ALTER-H-004: Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence (clinicaltrials.gov) -  Jan 17, 2023   
    P2,  N=30, Active, not recruiting, 
    The adverse events were mostly tolerable or relieved after treatment. Unknown status --> Active, not recruiting | N=48 --> 30 | Trial completion date: Jun 2022 --> Sep 2023 | Trial primary completion date: Dec 2021 --> Feb 2023
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Journal:  Anlotinib Suppressed Ovarian Cancer Progression via Inducing G2/M Phase Arrest and Apoptosis. (Pubmed Central) -  Jan 9, 2023   
    Furthermore, anlotinib inhibited tumor growth by inhibiting cell proliferation and suppressing ovarian cancer angiogenesis in vivo. This study demonstrated the extraordinary anti-ovarian cancer effect of anlotinib, which may provide a promising therapeutic strategy for ovarian cancer.
  • ||||||||||  cordycepin (OVI-123) / OncoVista
    Journal:  Efficacy and mechanism study of cordycepin against brain metastases of small cell lung cancer based on zebrafish. (Pubmed Central) -  Jan 8, 2023   
    This study demonstrated the extraordinary anti-ovarian cancer effect of anlotinib, which may provide a promising therapeutic strategy for ovarian cancer. Our work is the first to describe the mechanism of cordycepin against SCLC BM from the perspective of regulating the brain microenvironment, providing new evidence for the anti-tumor effect of cordycepin.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Journal, Metastases:  CT-Based Radiomics Can Predict the Efficacy of Anlotinib in Advanced Non-Small-Cell Lung Cancer. (Pubmed Central) -  Jan 6, 2023   
    In conclusion, radiomics has accurate predictions for the efficacy of anlotinib. CE-CT-based radiomic models have the best predictive potential in predicting the efficacy of anlotinib, and model predictions become better when they are combined with clinical characteristics.
  • ||||||||||  Ivesa (firmonertinib) / Allist, ArriVent, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial primary completion date, Metastases:  FOCUS-A: Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (clinicaltrials.gov) -  Jan 6, 2023   
    P2,  N=40, Recruiting, 
    CE-CT-based radiomic models have the best predictive potential in predicting the efficacy of anlotinib, and model predictions become better when they are combined with clinical characteristics. Trial primary completion date: Nov 2022 --> Nov 2023
  • ||||||||||  Baizean (tislelizumab) / BeiGene, Novartis, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Journal:  Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma. (Pubmed Central) -  Jan 4, 2023   
    The case firstly demonstrated the efficacy of tislelizumab combined with anlotinib in the second-line management of MPM. Thus, immunotherapy combined with small-molecule multi-target anti-angiogenic medication may be alternative for the second-line schemes of MPM.
  • ||||||||||  Enrollment open, Metastases:  BCTOP-L-M05: SNF Platform Study of HR+/ HER2-advanced Breast Cancer (clinicaltrials.gov) -  Jan 4, 2023   
    P2,  N=140, Recruiting, 
    Thus, immunotherapy combined with small-molecule multi-target anti-angiogenic medication may be alternative for the second-line schemes of MPM. Not yet recruiting --> Recruiting
  • ||||||||||  Enrollment open, Trial initiation date, Trial primary completion date, Combination therapy, Metastases:  CHANCE2201: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC (clinicaltrials.gov) -  Dec 29, 2022   
    P=N/A,  N=474, Recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Apr 2022 --> Dec 2022 | Trial primary completion date: Aug 2022 --> Aug 2023 Not yet recruiting --> Recruiting | Initiation date: Apr 2022 --> Dec 2022 | Trial primary completion date: Aug 2022 --> Aug 2023
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Journal, Metastases:  Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients. (Pubmed Central) -  Dec 27, 2022   
    The most common grade 3 and 4 adverse events were platelet count decrease (25.0%), diarrhea (7.1%), and oral mucositis (5.4%). Anlotinib-based treatment showed good efficacy and manageable toxicity in multi-line treatment of MBC patients who failed the standard treatment.
  • ||||||||||  Review, Checkpoint inhibition:  Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review. (Pubmed Central) -  Dec 20, 2022   
    However, the patient still benefited when switching to the programmed cell death receptor-1 (PD-1) inhibitor toripalimab in combination with chemotherapy in the fifth line...Following the progression of tislelizumab in combination with chemotherapy, the patient again profited after switching to durvalumab in combination with anlotinib and again achieved a progressive-free survival (PFS) of 11 months...Otherwise, immunotherapy postline enablement can still benefit patients, rechallenge after immune resistance is also possible in SCLC, and combination with chemotherapy or antiangiogenic therapy can improve the efficacy and prolong the survival. This will provide new ideas and options for the selection of treatment options for SCLC.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    New trial:  Irinotecan and Anlotinib for Epithelioid Sarcoma (clinicaltrials.gov) -  Dec 19, 2022   
    P=N/A,  N=10, Completed, 
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    New trial, Metastases:  Advanced or Metastatic Cholangiocarcinoma (clinicaltrials.gov) -  Dec 16, 2022   
    P=N/A,  N=60, Not yet recruiting,